The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data
Despite the availability of multiple treatment options, the prognosis for advanced gastric cancer (AGC) remains poor and more effective treatment options are needed. Ramucirumab is an established and recommended second-line treatment for AGC. In recently completed and ongoing clinical trials, ramuci...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2022-07, Vol.18 (21), p.2709-2721 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2721 |
|---|---|
| container_issue | 21 |
| container_start_page | 2709 |
| container_title | Future oncology (London, England) |
| container_volume | 18 |
| creator | Iwasa, Satoru Bando, Hideaki Piao, Yongzhe Yoshizawa, Kenichi Yamaguchi, Kensei |
| description | Despite the availability of multiple treatment options, the prognosis for advanced gastric cancer (AGC) remains poor and more effective treatment options are needed. Ramucirumab is an established and recommended second-line treatment for AGC. In recently completed and ongoing clinical trials, ramucirumab has been investigated in combination with new therapeutics and in new clinical settings to address the unmet treatment needs of AGC. In this review, the findings of recent clinical trials are discussed. The aims of this review are to present the current picture of ramucirumab-containing regimens in AGC and offer practical guidance on the clinical position and target populations of ramucirumab-containing regimens in light of emerging therapeutic developments. |
| doi_str_mv | 10.2217/fon-2022-0281 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_fon_2022_0281</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35703103</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-d5b5c9e4c35e7ac053b456fae2cab7310b5be616834ee3b8fb1b7cc9f60b61e3</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMo7rp69Cr5A9GkSZvWmyx-wYKXvZdkOlkj23ZJ2hX_vSlVb17mA555YR5CrgW_zTKh71zfsYxnGeNZKU7IUmilWCm5OE2z0hUrikotyEWMH5wrLXN-ThYy11wKLpdk3L4jhb3vPJg9PfTRD77vaO9oMO0IPoytsQz6bjCJ6XY04M632EXq-kBNczQdYEN3Jg7BA4VpDffUJO7o8XMK-ktPRKqNGcwlOXNmH_Hqp6_I9ulxu35hm7fn1_XDhoEss4E1uc2hQgUyR22A59KqvHAGMzBWpwdsbrEQRSkVorSls8JqgMoV3BYC5YqwORZCH2NAVx-Cb034qgWvJ3t1sldP9urJXuJvZv4w2habP_pXVwKqGXDjMAaM4DH9W89buvDgO_wn_BsJ2oF4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data</title><source>MEDLINE</source><source>PubMed Central</source><creator>Iwasa, Satoru ; Bando, Hideaki ; Piao, Yongzhe ; Yoshizawa, Kenichi ; Yamaguchi, Kensei</creator><creatorcontrib>Iwasa, Satoru ; Bando, Hideaki ; Piao, Yongzhe ; Yoshizawa, Kenichi ; Yamaguchi, Kensei</creatorcontrib><description>Despite the availability of multiple treatment options, the prognosis for advanced gastric cancer (AGC) remains poor and more effective treatment options are needed. Ramucirumab is an established and recommended second-line treatment for AGC. In recently completed and ongoing clinical trials, ramucirumab has been investigated in combination with new therapeutics and in new clinical settings to address the unmet treatment needs of AGC. In this review, the findings of recent clinical trials are discussed. The aims of this review are to present the current picture of ramucirumab-containing regimens in AGC and offer practical guidance on the clinical position and target populations of ramucirumab-containing regimens in light of emerging therapeutic developments.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2022-0281</identifier><identifier>PMID: 35703103</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; gastric cancer ; gastroesophageal cancer ; Humans ; Paclitaxel - therapeutic use ; Prognosis ; Ramucirumab ; Stomach Neoplasms - drug therapy ; VEGFR2</subject><ispartof>Future oncology (London, England), 2022-07, Vol.18 (21), p.2709-2721</ispartof><rights>2022 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-d5b5c9e4c35e7ac053b456fae2cab7310b5be616834ee3b8fb1b7cc9f60b61e3</citedby><cites>FETCH-LOGICAL-c382t-d5b5c9e4c35e7ac053b456fae2cab7310b5be616834ee3b8fb1b7cc9f60b61e3</cites><orcidid>0000-0003-3863-9582 ; 0000-0001-7898-3041 ; 0000-0001-6887-5709 ; 0000-0001-5041-2765</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35703103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iwasa, Satoru</creatorcontrib><creatorcontrib>Bando, Hideaki</creatorcontrib><creatorcontrib>Piao, Yongzhe</creatorcontrib><creatorcontrib>Yoshizawa, Kenichi</creatorcontrib><creatorcontrib>Yamaguchi, Kensei</creatorcontrib><title>The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Despite the availability of multiple treatment options, the prognosis for advanced gastric cancer (AGC) remains poor and more effective treatment options are needed. Ramucirumab is an established and recommended second-line treatment for AGC. In recently completed and ongoing clinical trials, ramucirumab has been investigated in combination with new therapeutics and in new clinical settings to address the unmet treatment needs of AGC. In this review, the findings of recent clinical trials are discussed. The aims of this review are to present the current picture of ramucirumab-containing regimens in AGC and offer practical guidance on the clinical position and target populations of ramucirumab-containing regimens in light of emerging therapeutic developments.</description><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>gastric cancer</subject><subject>gastroesophageal cancer</subject><subject>Humans</subject><subject>Paclitaxel - therapeutic use</subject><subject>Prognosis</subject><subject>Ramucirumab</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>VEGFR2</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LxDAQhoMo7rp69Cr5A9GkSZvWmyx-wYKXvZdkOlkj23ZJ2hX_vSlVb17mA555YR5CrgW_zTKh71zfsYxnGeNZKU7IUmilWCm5OE2z0hUrikotyEWMH5wrLXN-ThYy11wKLpdk3L4jhb3vPJg9PfTRD77vaO9oMO0IPoytsQz6bjCJ6XY04M632EXq-kBNczQdYEN3Jg7BA4VpDffUJO7o8XMK-ktPRKqNGcwlOXNmH_Hqp6_I9ulxu35hm7fn1_XDhoEss4E1uc2hQgUyR22A59KqvHAGMzBWpwdsbrEQRSkVorSls8JqgMoV3BYC5YqwORZCH2NAVx-Cb034qgWvJ3t1sldP9urJXuJvZv4w2habP_pXVwKqGXDjMAaM4DH9W89buvDgO_wn_BsJ2oF4</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Iwasa, Satoru</creator><creator>Bando, Hideaki</creator><creator>Piao, Yongzhe</creator><creator>Yoshizawa, Kenichi</creator><creator>Yamaguchi, Kensei</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-3863-9582</orcidid><orcidid>https://orcid.org/0000-0001-7898-3041</orcidid><orcidid>https://orcid.org/0000-0001-6887-5709</orcidid><orcidid>https://orcid.org/0000-0001-5041-2765</orcidid></search><sort><creationdate>20220701</creationdate><title>The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data</title><author>Iwasa, Satoru ; Bando, Hideaki ; Piao, Yongzhe ; Yoshizawa, Kenichi ; Yamaguchi, Kensei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-d5b5c9e4c35e7ac053b456fae2cab7310b5be616834ee3b8fb1b7cc9f60b61e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>gastric cancer</topic><topic>gastroesophageal cancer</topic><topic>Humans</topic><topic>Paclitaxel - therapeutic use</topic><topic>Prognosis</topic><topic>Ramucirumab</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>VEGFR2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iwasa, Satoru</creatorcontrib><creatorcontrib>Bando, Hideaki</creatorcontrib><creatorcontrib>Piao, Yongzhe</creatorcontrib><creatorcontrib>Yoshizawa, Kenichi</creatorcontrib><creatorcontrib>Yamaguchi, Kensei</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iwasa, Satoru</au><au>Bando, Hideaki</au><au>Piao, Yongzhe</au><au>Yoshizawa, Kenichi</au><au>Yamaguchi, Kensei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>18</volume><issue>21</issue><spage>2709</spage><epage>2721</epage><pages>2709-2721</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Despite the availability of multiple treatment options, the prognosis for advanced gastric cancer (AGC) remains poor and more effective treatment options are needed. Ramucirumab is an established and recommended second-line treatment for AGC. In recently completed and ongoing clinical trials, ramucirumab has been investigated in combination with new therapeutics and in new clinical settings to address the unmet treatment needs of AGC. In this review, the findings of recent clinical trials are discussed. The aims of this review are to present the current picture of ramucirumab-containing regimens in AGC and offer practical guidance on the clinical position and target populations of ramucirumab-containing regimens in light of emerging therapeutic developments.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>35703103</pmid><doi>10.2217/fon-2022-0281</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-3863-9582</orcidid><orcidid>https://orcid.org/0000-0001-7898-3041</orcidid><orcidid>https://orcid.org/0000-0001-6887-5709</orcidid><orcidid>https://orcid.org/0000-0001-5041-2765</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2022-07, Vol.18 (21), p.2709-2721 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_crossref_primary_10_2217_fon_2022_0281 |
| source | MEDLINE; PubMed Central |
| subjects | Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects gastric cancer gastroesophageal cancer Humans Paclitaxel - therapeutic use Prognosis Ramucirumab Stomach Neoplasms - drug therapy VEGFR2 |
| title | The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T13%3A47%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20position%20of%20ramucirumab-containing%20regimens%20for%20advanced%20gastric%20cancer:%20a%20review%20of%20clinical%20trial%20data&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Iwasa,%20Satoru&rft.date=2022-07-01&rft.volume=18&rft.issue=21&rft.spage=2709&rft.epage=2721&rft.pages=2709-2721&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2022-0281&rft_dat=%3Cpubmed_cross%3E35703103%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35703103&rfr_iscdi=true |